Nilofabicin

Nilofabicin is an enoyl- (acyl-carrier protein) reductase (FabI) inhibitor. Nilofabicin had an MIC (90) of 0.5 microg/ml for Staphylococcus aureus strains and was more potent than either linezolid or vancomycin[1].

Product Specifications

CAS Number

[934628-27-0]

Product Name Alternative

CG-400549

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Antibiotic; Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/nilofabicin.html

Purity

99.58

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1C=C(OCCC2=CC=CS2)C=CN1CC3=CC=CC(N)=C3C

Molecular Formula

C19H20N2O2S

Molecular Weight

340.44

Precautions

H302, H315, H319, H335

References & Citations

[1]Jong Hwa Yum, et, al. In Vitro Activities of CG400549, a Novel FabI Inhibitor, against Recently Isolated Clinical Staphylococcal Strains in Korea. Antimicrob Agents Chemother. 2007 Jul; 51 (7) : 2591–2593.